People: AMAG Pharmaceuticals Inc (AMAG.O)

AMAG.O on Nasdaq

22.25USD
24 May 2013
Price Change (% chg)

$0.31 (+1.41%)
Prev Close
$21.94
Open
$21.89
Day's High
$22.35
Day's Low
$21.76
Volume
77,776
Avg. Vol
139,174
52-wk High
$25.67
52-wk Low
$13.25

Search Stocks

Summary

Name Age Since Current Position

William Heiden

 52 2012 President, Chief Executive Officer, Director

Scott Holmes

 37 2012 Principal Financial Officer, Vice President - Finance, Chief Accounting Officer, Controller

Frank Thomas

 42 2012 Chief Operating Officer, Executive Vice President

Greg Madison

 2013 Executive Vice President, Chief Commercial Officer

Christopher White

 50 2011 Chief Business Officer, Senior Vice President - Business Development and Corporate Planning

Joseph Bonventre

 2008 Independent Director

Rajiv De Silva

 46 2012 Independent Director

Michael Narachi

 52 2006 Independent Director

Robert Perez

 48 2009 Independent Director

Lesley Russell Cooper

 2009 Independent Director

Gino Santini

 56 2012 Independent Director

Davey Scoon

 66 2006 Independent Director

Amy Sullivan

 Vice President, Corporate Communication, Investor Relation
» Insider Trading

Biographies

Name Description

William Heiden

 Mr. William K. Heiden has been appointed as President, Chief Executive Officer, Director of AMAG Pharmaceuticals, Inc., effective May 14, 2012. Mr. Heiden is an experienced pharmaceutical and biotechnology executive who is joining AMAG from GTC Biotherapeutics, Inc., where he has served as president and chief executive officer since June 2010. Mr. Heiden has served and will continue to serve as chairman of GTC Biotherapeutics following commencement of his employment with AMAG. Prior to joining GTC Biotherapeutics, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals, Inc., a pharmaceutical company, from September 2004 until December 2008. Prior to joining Elixir Pharmaceuticals, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (which was acquired by GlaxoSmithKline plc), from 2002 to 2004. From 1987 to 2002, Mr. Heiden progressed through various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. Mr. Heiden serves on the board of directors of LFB Biotechnologies S.A.S., a private French biotechnology company. Mr. Heiden holds an M.B.A. from Cornell University's Johnson Graduate School of Management, a M.I.M. degree from the University of Louvain and a B.A. degree from the University of Florida.

Scott Holmes

 Mr. Scott A. Holmes is Principal Financial Officer, Vice President - Finance, Chief Accounting Officer, Controller of AMAG Pharmaceuticals, Inc. He was appointed as Principal Financial Officer of the Company effective March 1, 2012. He currently serves as Company’s Vice President - Finance, Chief Accounting Officer, Controller. Mr. Holmes joined the Company in September 2011. In his current position, Mr. Holmes is primarily responsible for the Company’s accounting, financial and tax reporting functions. Prior to joining the Company, Mr. Holmes served as Vice President of Finance and Treasurer of Molecular Biometrics Inc., a commercial stage medical diagnostics company from June 2010 to September 2011. From August 2009 to June 2010, Mr. Holmes was Vice President of Finance & Administration of On-Q-ity Inc., an oncology diagnostics company. Prior to On-Q-ity Inc., Mr. Holmes served as a consultant with Altman & Company, a consulting firm, from January 2009 to August 2009. Prior to 2009, he spent five years at Dynogen Pharmaceuticals, Inc., a privately held pharmaceutical company, where he was Vice President Finance & Administration and Treasurer. Mr. Holmes also served as the Controller at Keryx Biopharmaceuticals, Inc., a publically held biotechnology company. Mr. Holmes holds a dual Master of Science/Masters of Business Administration degree from Northeastern University Graduate School of Business Administration as well as a Bachelor in History from Middlebury College.

Frank Thomas

 Mr. Frank E. Thomas serves as Chief Operating Officer, Executive Vice President of AMAG Pharmaceuticals Inc. He is no longer Interim President and Chief Executive Officer of the Company, effective May 14, 2012. Prior to joining the Company, Mr. Thomas served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., or Molecular Biometrics, from 2008 until 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., or Critical Therapeutics, from 2004 until 2008, where he was promoted to President and Chief Executive Officer from the position of Senior Vice President and Chief Financial Officer. Mr. Thomas also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas was the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc. Since 2007, Mr. Thomas has been a member of the Board of Directors of the Massachusetts Biotechnology Council. Mr. Thomas holds a B.B.A. in Business Administration from The University of Michigan, Ann Arbor.

Greg Madison

 Mr. Greg Madison has been appointed as Executive Vice President, Chief Commercial Officer of AMAG Pharmaceuticals, Inc. effective January 02, 2013. Since joining Genzyme in 2000, Mr. Madison developed commercial and general management experience as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as vice president and general manager for the renal division. In this role, Mr. Madison led a global organization with three marketed products in 76 countries and drove top-line growth, with combined revenues exceeding $1 billion. Mr. Madison's prior experience in the division includes serving as vice president and general manager of the U.S. business; vice president of U.S. sales; and vice president of U.S. marketing where he led all pre-launch preparation for Renvela, now the phosphate binder in the U.S. market. During his tenure with Genzyme, Mr. Madison also had roles in sales management, training, and managed markets and reimbursement. Prior to joining Genzyme, Mr. Madison spent five years at Jannsen Pharmaceuticals in sales and sales management roles, and began his career in the pharmaceutical industry in sales with Wyeth-Ayerst. Mr. Madison is an active Board member of, and a member of the Operations Committee with, Kidney Care Partners, a Washington DC based organization that is focused on legislative, regulatory and public policy issues related to patients with CKD. He holds a Bachelor of Business Administration in Finance from the University of Massachusetts, Amherst.

Christopher White

 Mr. Christopher G. White is Chief Business Officer, Senior Vice President - Business Development and Corporate Planning of AMAG Pharmaceuticals Inc. From 2005 through 2007, Mr. White was a Partner in the Pharmaceutical and Medical Products Practice at Accenture. Prior to Accenture, he was a Vice President and Partner in the Pharmaceuticals and Healthcare Practice at A.T. Kearney, Inc. from 1998 to 2005. From 1984 to 1998, Mr. White held positions of increasing responsibility at DuPont Pharmaceuticals Company, Merck & Co. Inc. and Arthur D. Little, respectively. Mr. White holds a B.S. in Chemical Engineering from Tufts University and an M.B.A. from Columbia University.

Joseph Bonventre

 Dr. Joseph Vincent Bonventre, M.D., Ph.D., is no longer Independent Director of AMAG Pharmaceuticals Inc., effective May 23, 2013. Dr. Bonventre has been the Director of the Renal Division of the Brigham and Women's Hospital since 2002, and is the Samuel A. Levine Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at the Massachusetts Institute of Technology. He has also been elected to the American Society of Clinical Investigation, the Association of American Physicians and the American Institute for Medical and Biological Engineering, and is a member of the Council and the past President of the American Society of Nephrology. Dr. Bonventre was the Chair of the Kidney Group of the Harvard Stem Cell Institute from 2004 to 2009 and co-chaired the Stem Cell, Regenerative Medicine and Tissue Engineering Center of the Brigham and Women's Hospital Research Institute from 2007 to 2011. He has received the Osler Medal of the Royal Society of Physicians and the Bywaters Award of the International Society of Nephrology. Dr. Bonventre is a charter member of the Board of Directors of the National Space Biology Research Institute and has been a member of the Board of Advisors of the Dean of the School of Engineering at Cornell University since 2004. He is past President and currently a member of the Board of Directors of the National Kidney Foundation Serving New England. He co-founded Patientkeeper Inc., a provider of integrated physician information systems, in the 1990s and Pacific Biosciences, Inc., a biotechnology company, in 2002. He has served on the Board of Directors of Patientkeeper, Inc. and the National Kidney Foundation of Massachusetts, Rhode Island, New Hampshire and Vermont and has been a member of the Scientific Advisory Board or Medical Advisory Board of a number of biotechnology and pharmaceutical companies. Dr. Bonventre holds a B.S. in Engineering Physics from Cornell University and an M.D. and Ph.D. in Biophysics from Harvard University.

Rajiv De Silva

 Mr. Rajiv De Silva is no longer Independent Director of AMAG Pharmaceuticals, Inc., effective May 23, 2013. Mr. De Silva is currently the President of Valeant Pharmaceuticals International, Inc., or Valeant, a public pharmaceutical company, and Chief Operating Officer of its Specialty Pharmaceuticals business. He joined Valeant in 2009 as Chief Operating Officer of its Specialty Pharmaceuticals business and is responsible for all specialty pharmaceutical operations. Prior to joining Valeant, Mr. De Silva held various leadership positions of increasing responsibility at Novartis AG, or Novartis, a public pharmaceutical company, from 2003 to 2009, including President, Novartis Vaccines USA and Head, Vaccines of the Americas, from 2007 to 2009. Prior to Novartis, Mr. De Silva was a partner at McKinsey & Company, a management consulting firm, where he focused his consulting practice on the pharmaceutical industry from 1995 to 2003. He holds a B.S. in Engineering from Princeton University, a M.S. from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania.

Michael Narachi

 Mr. Michael A. Narachi is Independent Director of AMAG Pharmaceuticals Inc., since November 8, 2006. Mr. Narachi is currently President and Chief Executive Officer of Orexigen Therapeutics, Inc., or Orexigen, a public biopharmaceutical company. Prior to joining Orexigen in 2009, he served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a biotechnology company, from 2006 until 2008. He served as Executive Chairman of the Board of Directors of Naryx Pharma, Inc., a pharmaceutical company, from August 2004 to April 2008. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., or Amgen, a public therapeutics company, where he served as General Manager of Amgen's Anemia Business from 1999 to 2004. Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, U.K.; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. Mr. Narachi received a B.S. and M.A. degree in Molecular Genetics from the University of California at Davis. He completed the Executive M.B.A. program at the Anderson Graduate School of Management at the University of California, Los Angeles.

Robert Perez

 Mr. Robert J. Perez is an Independent Director of AMAG Pharmaceuticals Inc. He is currently Executive Vice President and Chief Operating Officer of Cubist Pharmaceuticals, Inc., or Cubist, a public pharmaceutical company. Mr. Perez joined Cubist in 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection). Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS business unit from 2001 to 2003, where he was responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within the commercial organization. From 1987 to 1995 Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. He also served as a member of the Board of Directors of Epix Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from 2006 to 2009. Mr. Perez received a B.S. from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. Mr. Perez has been a member of the Board of Advisors of the Citizen School of Massachusetts since 2010 and served as a director of the Harvard-MIT Biomedical Enterprise Program from 2010 to 2011.

Lesley Russell Cooper

 Dr. Lesley Russell Cooper, MB.Ch.B., MRCP, is an Independent Director of AMAG Pharmaceuticals Inc., since December 2009. She is currently Senior Vice President and Head of Research and Development for Global Branded Products at Teva Pharmaceuticals, Inc., or Teva, a public pharmaceutical company. Dr. Russell was appointed to this role upon Teva's acquisition of Cephalon Inc., or Cephalon, a public pharmaceutical company, where she served as Executive Vice President and Chief Medical Officer. She joined Cephalon in 2000 as Vice President, Worldwide Clinical Research. Prior to Cephalon, Dr. Russell served as Vice President, Clinical Research at US Bioscience Inc., a pharmaceutical company, and held positions of increasing responsibility within US Bioscience Inc. from 1996 to 1999. From 1995 to 1996, she was a clinical research physician at Eli Lilly U.K. and a Medical Director at Amgen U.K. from 1992 to 1995. Dr. Russell was trained in Hematology/Oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children, Edinburgh. She received an MB.Ch.B. from the University of Edinburgh, Scotland and is a member of the Royal College of Physicians, United Kingdom. Dr. Russell is registered with the General Medical Council, United Kingdom.

Gino Santini

 Mr. Gino Santini has been appointed as Independent Director of AMAG Pharmaceuticals, Inc., effective February 7, 2012. From 1983 to 2010, Mr. Santini held a variety of commercial and operational roles at Eli Lilly and Company, or Eli Lilly, a public pharmaceutical company, serving most recently from 2007 to 2010 as Senior Vice President, Corporate Strategy and Business Development and as a member of the company's Executive Committee where he led corporate strategy and long-range planning, mergers and acquisitions, new product licensing, innovative financing of internal development projects and the expansion of Lilly Ventures in the United States and China. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. operations from 1999 to 2004 and President of the women's health franchise from 1997 to 1999. Mr. Santini currently serves on the Board of Directors of Allena Pharmaceuticals, Inc., a pharmaceuticals company, where he has been a director since February 2012. Mr. Santini also serves on the Board of Directors, as well as the Audit Committee and Nominating and Corporate Governance Committee of the Board of Directors, of Horizon Pharma, Inc., a public biopharmaceutical company, where he has been a director since February 2012. Mr. Santini is also a past Chairman of the Board of the National Pharmaceutical Council and of Noble of Indiana, a non-profit agency serving individuals with developmental disabilities. He also served on the Board of Directors for United Way and the Executive Committee and Board of Directors of the Indianapolis Chamber of Commerce. He holds an undergraduate degree in mechanical engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester.

Davey Scoon

 Mr. Davey S. Scoon, CPA, is Independent Director of AMAG Pharmaceuticals Inc., since December 2006. Mr. Scoon serves as Chairman of the Board of Directors of Tufts Health Plan, where he has been a director since 1981. He has been a member of the Board of Directors of Orthofix International, N.V., a medical device company, since 2011. Mr. Scoon also serves as Chairman of the Board of Trustees of Allianz Funds, a registered investment company consisting of 22 mutual funds, where he has been a director since 2006. He was the Chairman of the Audit Committee of Cardiokine, Inc., a pharmaceutical company, where he was a director from 2005 to 2011. Mr. Scoon has been an Adjunct Assistant Professor at Tufts University School of Medicine since 2005 and a lecturer in accounting at the University of Wisconsin since 2011. He also previously served as the Chairman of the Audit Committee of NitroMed, Inc., a public pharmaceutical company, from 2003 to 2009, and a member of the Board of Directors of Inotek Pharmaceuticals Corporation, a pharmaceutical company, from 2006 to 2009. From 2003 to 2005, Mr. Scoon was Chief Administrative and Financial Officer of Tom's of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as Chief Financial and Administrative Officer for Sun Life Financial U.S., and from 1999 to 2001, Mr. Scoon served as Vice President and Chief Financial Officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities, including Chief Financial Officer and Chief Operating Officer. Mr. Scoon holds a B.B.A. from the University of Wisconsin and an M.B.A. from Harvard Business School.

Amy Sullivan

Insider Trading

Name Shares Traded Price

HEIDEN WILLIAM K

 8,162 $25.03

HEIDEN WILLIAM K

 25,000 $0.00

HEIDEN WILLIAM K

 27,500 $0.00

THOMAS FRANK E

 12,500 $0.00

TOWNSEND SCOTT B

 7,500 $0.00

HEIDEN WILLIAM K

 14,400 $0.00

HOLMES SCOTT A

 2,500 $0.00

TOWNSEND SCOTT B

 4,400 $0.00

THOMAS FRANK E

 6,300 $0.00

MADISON GREG

 12,500 $0.00

MADISON GREG

 6,300 $0.00

HOLMES SCOTT A

 5,000 $0.00

WHITE CHRISTOPHER G

 10,000 $0.00

WHITE CHRISTOPHER G

 5,000 $0.00

WHITE CHRISTOPHER G

 400 $16.37

WHITE CHRISTOPHER G

 433 $16.39

WHITE CHRISTOPHER G

 833 $0.00

WHITE CHRISTOPHER G

 3,000 $15.80

WHITE CHRISTOPHER G

 3,000 $15.87

WHITE CHRISTOPHER G

 4,000 $0.00

WHITE CHRISTOPHER G

 4,000 $16.07

WHITE CHRISTOPHER G

 4,000 $16.03

WHITE CHRISTOPHER G

 10,000 $0.00

THOMAS FRANK E

 10,000 $15.60

THOMAS FRANK E

 20,000 $0.00
» Full list on Insider Trading
Search Stocks